| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Almitas Capital LLC | 5.4% | +4% | $3,927,216 | +$2,041,830 | 2,975,164 | +108% | Almitas Capital LLC | 31 Dec 2025 |
| Coastlands Capital Partners LP | 9.3% | $3,632,511 | 2,815,900 | Coastlands Capital LP | 28 May 2025 | |||
| Adjuvant Global Health Technology Fund, L.P. | 7.9% | $3,061,815 | 2,373,500 | Adjuvant Capital GP, L.P. | 31 Dec 2024 | |||
| Easom Eric | 7.9% | +28% | $2,946,245 | +$447,311 | 2,232,004 | +18% | Eric Easom | 31 Dec 2025 |
| Brii Biosciences Ltd | 3.1% | $1,196,089 | 927,201 | Brii Biosciences Limited | 31 Dec 2024 | |||
| BML Investment Partners, L.P. | 1.4% | -85% | $551,387 | -$3,599,088 | 427,432 | -87% | BML Investment Partners, L.P. | 17 Jun 2025 |
As of 31 Dec 2025, 37 institutional investors reported holding 8,664,575 shares of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX). This represents 16% of the company’s total 55,095,630 outstanding shares.
The largest institutional shareholders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) together control 16% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Almitas Capital LLC | 2.7% | 1,479,129 | +3.6% | 0.37% | $1,686,207 |
| VANGUARD GROUP INC | 2% | 1,080,070 | 0% | 0% | $1,231,280 |
| Pfizer Inc | 1.3% | 715,295 | 0% | 0.34% | $815,436 |
| Stonepine Capital Management, LLC | 1.1% | 627,668 | +11% | 0.57% | $715,542 |
| Peapod Lane Capital LLC | 1.1% | 593,396 | +0.71% | 0.58% | $676,471 |
| BANK OF NOVA SCOTIA | 0.83% | 459,194 | 0% | 0% | $523,481 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 0.78% | 431,760 | -5.4% | 0.03% | $492,206 |
| BANK OF MONTREAL /CAN/ | 0.77% | 422,077 | 0% | 0% | $481,168 |
| BANK OF AMERICA CORP /DE/ | 0.7% | 385,312 | +0% | 0% | $439,256 |
| RENAISSANCE TECHNOLOGIES LLC | 0.61% | 338,600 | -12% | 0% | $386,004 |
| BlackRock, Inc. | 0.59% | 323,335 | +0.76% | 0% | $368,602 |
| TWO SIGMA ADVISERS, LP | 0.48% | 264,900 | -1.1% | 0% | $301,986 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.46% | 251,875 | +1% | 0% | $287,199 |
| MORGAN STANLEY | 0.42% | 229,770 | +20% | 0% | $261,938 |
| TWO SIGMA INVESTMENTS, LP | 0.32% | 178,518 | -20% | 0% | $203,511 |
| Woodline Partners LP | 0.26% | 145,971 | 0% | $166,407 | |
| CITADEL ADVISORS LLC | 0.21% | 115,536 | +402% | 0% | $131,711 |
| MILLENNIUM MANAGEMENT LLC | 0.17% | 95,683 | 0% | $109,079 | |
| STATE STREET CORP | 0.16% | 87,002 | 0% | 0% | $99,182 |
| Rangeley Capital, LLC | 0.12% | 65,000 | 0% | 0.06% | $74,100 |
| Squarepoint Ops LLC | 0.11% | 61,612 | -4.1% | 0% | $70,238 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.11% | 59,900 | 0% | 0% | $68,286 |
| UBS Group AG | 0.1% | 56,668 | -0.05% | 0% | $64,601 |
| NORTHERN TRUST CORP | 0.08% | 43,196 | 0% | 0% | $49,243 |
| CAPTRUST FINANCIAL ADVISORS | 0.07% | 40,000 | 0% | 0% | $45,600 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 8,664,575 | $9,877,677 | +$437,838 | $1.14 | 37 |
| 2025 Q3 | 8,276,317 | $10,511,010 | +$7,414 | $1.27 | 35 |
| 2025 Q2 | 8,284,557 | $8,781,263 | -$8,600,258 | $1.06 | 36 |
| 2025 Q1 | 14,340,830 | $19,503,615 | -$264,699 | $1.36 | 37 |
| 2024 Q4 | 14,528,930 | $20,050,012 | +$893,482 | $1.38 | 37 |
| 2024 Q3 | 13,513,224 | $14,458,906 | -$16,315,888 | $1.07 | 31 |
| 2024 Q2 | 19,415,909 | $41,730,123 | -$1,462,207 | $2.15 | 45 |
| 2024 Q1 | 18,733,564 | $60,875,021 | -$18,042,573 | $3.25 | 54 |
| 2023 Q4 | 20,391,503 | $417,920,110 | +$9,592,150 | $20.49 | 51 |
| 2023 Q3 | 19,931,490 | $320,311,244 | +$132,978,201 | $16.08 | 37 |
| 2023 Q2 | 11,741,328 | $99,891,167 | +$18,097,549 | $8.50 | 30 |
| 2023 Q1 | 9,600,229 | $94,752,948 | -$1,565,644 | $9.87 | 37 |
| 2022 Q4 | 9,762,608 | $93,037,767 | -$3,679,262 | $9.53 | 35 |
| 2022 Q3 | 9,496,676 | $165,051,000 | +$1,938,968 | $17.38 | 35 |
| 2022 Q2 | 9,386,370 | $72,410,000 | +$2,199,519 | $7.75 | 32 |
| 2022 Q1 | 8,952,537 | $134,111,000 | +$134,111,000 | $15.07 | 18 |